S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC

Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.